No stone left unturned: Challenges encountered during recruitment of women with advanced ovarian cancer for a phase I study

被引:5
作者
Albrecht, Tara A. [1 ]
Taylor, Ann Gill [1 ]
机构
[1] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
关键词
Clinical trial research; Cancer; Recruitment; Research methodology; CLINICAL-TRIAL; MEDICINE USE; COMPLEMENTARY; ONCOLOGY; BARRIERS; MASSAGE; THERAPY;
D O I
10.1016/j.apnr.2013.05.003
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The recruitment and accrual of participants for cancer clinical trial research is often challenging. Chronic low accrual rates negatively influence the findings and generalizability that can be drawn from the available pool of research. There is a need for further evidence regarding both unsuccessful and successful approaches and useful strategies that investigators have used to counter common recruitment challenges. During recruitment for an intervention study examining the safety, efficacy, and feasibility of a potentially novel supportive therapy, a variety of steps were taken to avoid and subsequently overcome potential and real recruitment challenges the investigators faced. In this article the authors provide an overview of common recruitment challenges as well as the actual challenges encountered, procedures and strategies implemented to counter these challenges, while investigating the combined intervention of flaxseed oil, fasting, caffeine, and exercise in women with recurrent or multi-drug resistant stage HI or IV ovarian cancer. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:245 / 250
页数:6
相关论文
共 50 条
  • [21] Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer
    Roman Huber
    Dietrich Schlodder
    Carola Effertz
    Sabine Rieger
    Wilfried Tröger
    BMC Complementary and Alternative Medicine, 17
  • [22] Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
    Lee, Jung-Min
    Hays, John L.
    Chiou, Victoria L.
    Annunziata, Christina M.
    Swisher, Elizabeth M.
    Harrell, Maria I.
    Yu, Minshu
    Gordon, Nicolas
    Sissung, Tristan M.
    Ji, Jiuping
    Figg, William D.
    Minasian, Lori
    Lipkowitz, Stanley
    Wood, Bradford J.
    Doroshow, James
    Kohn, Elise C.
    ONCOTARGET, 2017, 8 (45) : 79175 - 79187
  • [23] Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
    K Yamaguchi
    T Shimamura
    I Hyodo
    W Koizumi
    T Doi
    H Narahara
    Y Komatsu
    T Kato
    S Saitoh
    T Akiya
    M Munakata
    Y Miyata
    Y Maeda
    H Takiuchi
    S Nakano
    T Esaki
    F Kinjo
    Y Sakata
    British Journal of Cancer, 2006, 94 : 1803 - 1808
  • [24] Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer
    Kimple, Randall J.
    Horton, Janet K.
    Livasy, Chad A.
    Shields, Janiel M.
    Lawrence, Julia A.
    Chiu, WingKeung M.
    Ivanova, Anastasia
    Ollila, David W.
    Carey, Lisa A.
    Halle, Jan S.
    Sartor, Carolyn I.
    Dees, E. Claire
    ONCOLOGIST, 2012, 17 (12) : 1496 - 1503
  • [25] A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer
    Murphy, Adrian G.
    Zahurak, Marianna
    Shah, Mirat
    Weekes, Colin D.
    Hansen, Aaron
    Siu, Lillian L.
    Spreafico, Anna
    LoConte, Noelle
    Anders, Nicole M.
    Miles, Tearra
    Rudek, Michelle A.
    Doyle, L. Austin
    Nelkin, Barry
    Maitra, Anirban
    Azad, Nilofer S.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1178 - 1188
  • [26] Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer
    Kim, Yeul Hong
    Seo, Hee Yeon
    Jeen, Yoon Tae
    Kim, Hoon-Kyo
    Shim, Byoung Yong
    Yang, Jinmo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 253 - 260
  • [27] Phase I Study of Docetaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer
    Hironaka, Shuichi
    Yamazaki, Kentaro
    Taku, Keisei
    Yokota, Tomoya
    Shitara, Kohei
    Kojima, Takashi
    Ueda, Shinya
    Machida, Nozomu
    Muro, Kei
    Boku, Narikazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (11) : 1014 - 1020
  • [28] Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit
    Fu, Siqing
    McQuinn, Lacey
    Naing, Aung
    Wheler, Jennifer J.
    Janku, Filip
    Falchook, Gerald S.
    Piha-Paul, Sarina A.
    Tu, Dennis
    Howard, Adrienne
    Tsimberidou, Apostolia
    Zinner, Ralph
    Hong, David S.
    Kurzrock, Razelle
    ONCOLOGIST, 2013, 18 (12) : 1315 - 1320
  • [29] Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study
    Syrios, John
    Kouroussis, Charalambos
    Kotsakis, Athanasios
    Kentepozidis, Nikolaos
    Kontopodis, Emmanouil
    Kalbakis, Kostas
    Vardakis, Nikolaos
    Hatzidaki, Dora
    Polyzos, Aris
    Georgoulias, Vassilis
    MINERVA GINECOLOGICA, 2019, 71 (03): : 182 - 190
  • [30] Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer
    Wang, Biyun
    Zhang, Wen
    Hong, Xiaonan
    Guo, Ye
    Li, Jin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 213 - 218